about
Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial.Metformin increases plasma ghrelin in Type 2 diabetes.The Diabetes Excess Weight Loss (DEWL) Trial: a randomised controlled trial of high-protein versus high-carbohydrate diets over 2 years in type 2 diabetes.Transitioning to a national (New Zealand) sole supply scheme for glucose meters: lessons learned, problems yet to be solved.High intensity interval training in a real world setting: a randomized controlled feasibility study in overweight inactive adults, measuring change in maximal oxygen uptake.Postprandial capillary-venous glucose gradient in Type 1 diabetes: magnitude and clinical associations in a real world settingRandomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3.Do thiazide diuretics alter the pharmacokinetics of metformin in patients with type 2 diabetes already established on metformin?Incorrect AM/PM Insulin Pump Clock Settings Can Result in an Unstable Insulin Dosing Feedback Loop.Comparison of blood glucose meters in a New Zealand diabetes centre.Prospective audit of conversion from regular to lispro insulin during routine clinical care.Laboratory diagnosis of gestational diabetes: An in silico investigation into the effects of pre-analytical processing on the diagnostic sensitivity and specificity of the oral glucose tolerance test.How Much Hemolysis Is Acceptable When Undertaking Deep Lancing for Finger Stick Derived Capillary Plasma Glucose Measurement?What is the lower limit for postprandial venous plasma glucose in healthy young adults?Impact of prandial status on the comparison of capillary glucose meter and venous plasma glucose measurements in healthy volunteers.Collection tubes containing citrate stabiliser over-estimate plasma glucose, when compared to other samples undergoing immediate plasma separation.Assessment of glucose meter performance at the antenatal diabetes clinic: exploration of patient-related and pre-analytical factors.Treatment satisfaction after commencement of insulin in Type 2 diabetes.How Satisfied Are Patients When Their Choice of Funded Glucose Meter Is Restricted to a Single Brand?Variation of betaine, N,N-dimethylglycine, choline, glycerophosphorylcholine, taurine and trimethylamine-N-oxide in the plasma and urine of overweight people with type 2 diabetes over a two-year period.Capillary Samples and Hemolysis: Further Considerations.Overnight urinary growth hormone measurement in the diagnosis of acromegalyIntravenous catheter-associated Staphylococcus epidermidis bacteremia in hematology/oncology patientsSelf-reported changes in capillary glucose and insulin requirements during the menstrual cycleThe prognostic significance of urinary albumin in Polynesians with non-insulin-dependent diabetesMetabolic control and psychological sense of control in women with diabetes mellitus. Alternative considerations of the relationshipA population-based study of bone mineral density in women with longstanding type 1 (insulin dependent) diabetesMeasurement of breath acetone concentrations by selected ion flow tube mass spectrometry in type 2 diabetesExtreme urinary betaine losses in type 2 diabetes combined with bezafibrate treatment are associated with losses of dimethylglycine and choline but not with increased losses of other osmolytesPlasma glucose measurement in diabetes: impact and implications of variations in sample collection procedures with a focus on the first hour after sample collectionElectronic informed consent: the need to redesign the consent process for the digital ageDiagnosing the Underlying Cause of Mild Hyperglycemia Using Interstitial Glucose Data
P50
Q33421537-B698F1E4-FE67-4113-AD62-C551281945ACQ33607992-01E3C174-52E4-4AD6-AFD3-C4C87CCA4AE2Q34635477-216A46BB-292C-4BAF-B519-2D6BD9035121Q35682828-11E451BD-76BF-4260-9F00-AE9DDB4E6C4DQ37472760-392E037D-667C-44CB-BD91-0D5656064EADQ41464794-32F91298-457D-4934-9890-B666781245D5Q41673741-91150D08-000A-4DAE-9070-5D2BD7D0A8C8Q43146761-B2EC4C04-D137-408F-9DA1-7367B64EECC2Q43401748-09DEC8CB-378E-4FD0-AE9E-E6B5F0354224Q46005048-05897720-6CE3-44B3-B921-4ABCF38AB820Q47262110-FB66BC05-96E3-4A10-ABF4-CFF04AA39844Q50217147-03121E96-4C77-4F56-85A0-0A83E51E7A60Q50301052-8044CAD8-6D93-4EEF-B0F1-DA3E41AAA0C6Q51334776-E89A0710-810A-444A-9440-1DA5FC0E2559Q51349062-8862E577-5623-494D-8109-4D4083885561Q53090502-A5E55D21-D7CE-422A-8F08-552011E9CAF5Q53125614-3726F876-EFA3-45B2-9EEA-D3E07BA34E7BQ53320215-1E671565-09B6-492A-9E1C-8AB8FDED558AQ53762190-840D859B-6B4B-4283-83A3-6665A8AF43A0Q54247889-0872991F-EEF2-4FB9-A165-72A651C0AC76Q55393256-9E013E74-5D67-47A5-B3CC-A0C9C8523D82Q68580017-783E0DEA-D507-472C-8442-EB79C40DAE7EQ69439539-F046CAA5-B44B-4DD7-991C-6E93383EB8B5Q71516897-C28C38C1-138E-4384-B72E-8A5CFC769BC3Q72533761-998F0764-4A58-47CB-A3D2-7B015F3E2561Q73303696-9D864DCE-AA0E-4222-9A34-4F29DF80B3FDQ77070475-96D5B627-B32F-4813-ACA6-A3D04252651FQ82767315-857CF365-D571-4078-8F69-A7C0C4E2223EQ87441220-E2F5A3FD-8B72-48A4-B5A7-838492E8666FQ87624693-77714775-8F0D-46A9-87EC-186CF3F3EBEAQ91800846-8FDA4907-A918-433D-A727-E12F666B554CQ95938955-EF01A439-35AC-411B-A517-714C018496C5
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Helen Lunt
@ast
Helen Lunt
@en
Helen Lunt
@es
Helen Lunt
@nl
Helen Lunt
@sl
type
label
Helen Lunt
@ast
Helen Lunt
@en
Helen Lunt
@es
Helen Lunt
@nl
Helen Lunt
@sl
prefLabel
Helen Lunt
@ast
Helen Lunt
@en
Helen Lunt
@es
Helen Lunt
@nl
Helen Lunt
@sl
P106
P1153
55882074600
P21
P31
P496
0000-0003-0069-7402